London stocks were set to open in calm trading on Monday as investors looked ahead to earnings results and a busy week for the central bank.
The FTSE 100 was called to open unchanged at 7,635.
CMC market Analyst Michael Hewson said: “European markets are likely to enter the new week in a fairly cautious manner, given the strong finish seen last weekend. We look forward to seeing the ECB’s It’s going to start with foresight.” We’ll be posting the latest Q1 GDP statistics for Germany, France, Italy, Spain and the EU, as well as his CPI bulletin data for January later in the week.
“The ECB could be in the position this weekend to try to justify not cutting interest rates when the eurozone is in a technical recession, increasing pressure to cut rates early as early as April. It will increase.”
In corporate news, ryanair The company lowered its full-year profit forecast after a 93% drop in third-quarter net profit as higher fuel costs offset higher sales.
Net profit fell to 15 million euros from 211 million euros in the same period last year.
The company now expects FY24 profit after tax to be between €1.85 billion and €1.95 billion, revised down from its previous forecast of €1.85 billion to €2.05 billion. There is.
iron ore pellet producers Felexpo Ukraine’s Court of Appeals has announced that it has granted a claim of approximately $125 million against Ukraine as part of a long-running lawsuit against its largest shareholder.
The company said it would appeal to the Supreme Court of Ukraine.
London-listed Ferexpo is facing multiple lawsuits and an investigation by Ukrainian authorities seeking to recover assets from founder and 49.5% shareholder Kostyantyn Zhebago.
The company says its operations will not be affected. Further announcements will be made “as appropriate.”
Major biopharmaceutical company GSK has been given the green light by European regulators to sell Omjala, a treatment for patients with a rare type of blood cancer.
GSK announced that Omjjara, the brand name for momelotinib, has received marketing authorization from the European Commission, allowing the company to sell the drug to patients and patients across the EU and the EEA-EFTA states of Iceland and Liechtenstein. Permission was granted to make it available to workers. And Norway.
In a separate statement, GSK also said that the European Medicines Agency had accepted for regulatory review the Aleksby drug, developed for the prevention of respiratory syncytial virus (RSV) disease.
tritax big box The update reported on the resilience of the occupational market and stable investment yields. The FTSE 250 real estate investment trust has announced that it will achieve 22.1 million sq ft of lettings in the UK in 2023, with a further 11.1 million sq ft under offer, maintaining pre-COVID-19 levels. We also added £7.8m of annual contracted rent through development lettings, actively managed our portfolio for optimal performance, and strengthened our balance sheet with significant liquidity and no short-term debt maturities.